Barinthus Biotherapeutics plc American Depositary Shares (BRNS)
Company News
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
On Friday, Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc, released topline final data from the APOLLO trial (HPV001) Phase 1b/2 dose-ranging trial of VTP-200 in women with low-grade cervical lesions associated with persistent High-risk human papillomavirus (hrHPV) infection. “While we didn’t observe a significant improvement from VTP-200 in the overall pooled results, we did observe positive trends in the highest dose cohorts,” said Bill Enright, CEO. The APOLLO study met its primary safety endpoint, demonstrating that VTP-200 was generally well-tolerated and was administered with no treatment-related grade 3 or higher unsolicited AEs and no treatment-related SAEs. The highest hrHPV clearance rate of 60% at Month 12 was observed in group 2, which included the highest dose of ...Full story available on Benzinga.com
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -54.05% and 2.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?